BOD.AX Shariah Compliance
Screening Methodology: AAOIFI
DOUBTFUL
Last Updated: July 31, 2025
Report Source: 2025 2nd Quarter Report

Bod Science Ltd. Stock Analysis BOD.AX
Bod Science Ltd. operates as a developer, manufacturer, distributor, importer, exporter and marketer of skincare, beauty, and health industries for the natural segment of the market. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-10-27. The firm is focused on progressing research and development with a defined clinical trial pathway to commercialize and deliver products for consumer and medical markets. The principal activities of the Company are the development and distribution of therapeutic medicinal cannabis products based on good manufacturing practice (GMP) certified cannabis extracts for medical markets in Australia and the United Kingdom, as well as the development of cannabidiol (CBD) and hemp products for consumer markets in Australia, the United Kingdom, Europe, and the United States. The Company’s segments include Medical, Over the counter cannabidiol/Hemp (OTC CBD/Hemp), OTC Herbals, and Corporate. The firm also owns the Aqua Phase delivery technology. The technology delivers a GMP active pharmaceutical ingredient (API) or compound in dry form for use in products.
Read More Bod Science Ltd (BOD.AX) Chart
Key Statistics of Bod Science Ltd (BOD.AX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
AUD0.03Volume
38.60KP/E Ratio (TTM)
16.4352 Week Range
Market Cap
4.26MAvg. Volume
132.45KDividend Yield
-Financial Metrics & Statements of Bod Science Ltd (BOD.AX)
FAQ's for Bod Science Ltd (BOD.AX)
- According to Musaffa’s Shariah screening methodology, Bod Science Ltd (BOD.AX) is currently classified as DOUBTFUL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.